StockDuty ← Dashboard Sep 17, 2026 05:51 AM ET
SignalFDA/Bio

Genentech’s Lunsumio-Based Regimen Significantly Improves Progression-Free Survival in Follicular Lymphoma in Phase III CELESTIMO Study

Phase III CELESTIMO data show Lunsumio regimen significantly improves progression-free survival in follicular lymphoma.

Phase III CELESTIMO data show Lunsumio regimen significantly improves progression-free survival in follicular lymphoma.
Phase III CELESTIMO data show Lunsumio regimen significantly improves progression-free survival in follicular lymphoma. — impact context not separately stored; see What changed.
Sources